Lumos Diagnostics has expanded the availability of its FebriDx test to 43 WellStreet clinics in Georgia and Michigan following FDA approval and CLIA waiver.

Lumos Diagnostics Expands FebriDx Reach Amidst Regulatory Milestones Lumos Diagnostics is expanding its FebriDx test to 43 WellStreet clinics in Georgia and Michigan after receiving FDA CLIA waiver. This allows wider use in doctor's offices and clinics. #FebriDx, #LumosDiagnostics, #WellStreet, #FDA, #CLIAWaiver https://newsletter.tf/lumos-diagnostics-febridx-wellstreet-clinics-fda-waiver/

Lumos Diagnostics' FebriDx test is now available in 43 WellStreet clinics, a significant increase from its previous single-site trial. This expansion follows a key FDA approval. #FebriDx, #LumosDiagnostics, #WellStreet, #FDA, #CLIAWaiver https://newsletter.tf/lumos-diagnostics-febridx-wellstreet-clinics-fda-waiver/